Misonix Launches Faster SonicOne® Ultrasonic Debridement Procedure

FARMINGDALE, N.Y., July 9, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today released a newly-developed, faster SonicOne O.R. Ultrasonic wound debridement procedure. The procedure is enabled by a new single-use disposable debridement probe with increased ultrasonic amplitude that allows surgeons using the SonicOne device to potentially reduce the operating room time necessary to complete a procedure by up to 50 percent.

Dr. Peter Blume, Assistant Clinical Professor of Orthopedics and Rehabilitation in the Department of Orthopedics, Section of Podiatric Surgery at the Yale University School of Medicine in New Haven, CT, considers the launch of the new SonicOne procedure as an important advancement in the technology.  "The addition of the new faster Ultrasound Assisted Debridement procedure to the SonicOne O.R. system will allow me to utilize the already proven advantages in wound care to larger, more complex wound surfaces. This creates an opportunity to treat a larger segment of the patient population, who had not previously been eligible for the benefits of this approach."

"The benefits of ultrasonic debridement have been well received by the wound community," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Our latest advancement in bringing speed to the SonicOne product line allows users to take advantage of those ultrasonic benefits without compromising procedure times. These advancements extend our leadership position in the wound debridement field."

The SonicOne O.R. System is an innovative ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process.

The new SonicOne procedure will be sold and distributed through the Misonix sales team and the Company's distributor network in the United States.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com